|CHERVYAKOVA, OLGA - Institute Of Kazakhstan|
|ZAITSEV, VALENTIN - Institute Of Kazakhstan|
|ISKAKOV, BULAT - Institute Of Kazakhstan|
|TAILAKOVA, ELMIRA - Institute Of Kazakhstan|
|STROCHKOV, VITALIY - Institute Of Kazakhstan|
|SULTANKULOVA, KULYAISAN - Institute Of Kazakhstan|
|SANDYBAYEV, NURLAN - Institute Of Kazakhstan|
|STANBEKOVA, GULSHAN - Institute Of Kazakhstan|
|BEISENOV, DANIYAR - Institute Of Kazakhstan|
|ABDURAIMOV, YERGALI - Institute Of Kazakhstan|
|MAMBETALIYEV, MURATBAY - Institute Of Kazakhstan|
|SANSYZBAY, ABYLAY - Institute Of Kazakhstan|
|KOVALSKAYA, NATALIA - Pennsylvania University|
Submitted to: Viruses
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 5/30/2016
Publication Date: 6/7/2016
Citation: Chervyakova, O.V., Zaitsev, V.L., Iskakov, B.K., Tailakova, E.T., Strochkov, V.M., Sultankulova, K.T., Sandybayev, N.T., Stanbekova, G.E., Beisenov, D.K., Abduraimov, Y.O., Mambetaliyev, M., Sansyzbay, A., Kovalskaya, N.Y., Nemchinov, L.G., Hammond, R. 2016. Recombinant sheep pox virus proteins elicit neutralizing antibodies. Viruses. 8(6)159.
Interpretive Summary: Sheep pox, caused by sheep pox virus, is a highly contagious viral disease of small ruminants, and is endemic in the Near East and Central Asia, India and China, as well as in Central and Southern Africa. The disease has a major impact on sheep production in many countries. A cultured vaccine based on the virus is used for control of the disease; however, there are limitations to the use of live vaccines in the areas that are free from this disease. We found a way to use proteins produced by the virus, instead of live virus, to make new vaccines for trials. The report will be of interest to an international audience of researchers, clinicians, and representatives of industry, academia, and government organizations with an interest in the production of recombinant medicines, vaccinology, immunology, and animal health.
Technical Abstract: The aim of this study was to evaluate the immunogenicity and neutralizing activity of bacterially-expressed sheep pox virus (SPPV) structural proteins as candidate subunit vaccines to control sheep pox disease. SPPV structural proteins were identified by sequence homology with proteins from vaccinia virus. Four SPPV proteins that are orthologs of immunodominant L1R, A4L, A27L, and A33R vaccinia virus proteins were expressed in Escherichia coli (DE3). Western blot analysis of the antigenicity of recombinant proteins showed that they were recognized by sheep pox-immune serum. The sera to the recombinant proteins L1R, A27L, and A33R demonstrated virus-neutralizing activity in cell culture. To our knowledge, this is the first report of the bacterial expression of recombinant SPPV structural proteins and the demonstration of the neutralizing activities of antisera raised to these proteins.